Every recall we track for Breckenridge Pharmaceutical, Inc. — 35 in all — plus the complaints and injury reports the public filed about them.
Breckenridge recalls 30mg Duloxetine Delayed-Release Capsules with N-nitroso-duloxetine impurity above FDA limits. This impurity may cause serious health risks. Consumers should contact the company for details.
Breckenridge Pharmaceutical recalls 60mg Duloxetine Delayed-Release Capsules due to N-nitroso-duloxetine impurity exceeding FDA limits. Rx-only medication with specific lot numbers and expiration dates.
Breckenridge Pharmaceutical recalls 60mg Duloxetine capsules due to N-nitroso-duloxetine impurity exceeding FDA limits. Affected lots: 241069C (exp 05/31/2027).
Breckenridge recalls 60mg Duloxetine Delayed-Release Capsules with N-nitroso-duloxetine impurity above FDA limits. Rx-only bottles from Towa Pharmaceuticals, lots 240947C/240962C, expiring 04/2027.
Breckenridge Pharmaceutical recalls 60mg Duloxetine Delayed-Release Capsules due to N-nitroso-duloxetine impurity exceeding FDA limits. Affected lots manufactured in Spain, distributed in the US. Consumers should contact for remedy.
Breckenridge Pharmaceutical recalls 60mg Duloxetine Delayed-Release Capsules due to N-nitroso-duloxetine impurity exceeding safety limits. Affected products include 90-count (NDC 51991-748-90) and 1000-count (NDC 51991-748-10) bottles. No remedy specified in recall notice.
Breckenridge Pharmaceutical recalls 30mg Duloxetine capsules due to N-nitroso-duloxetine impurity exceeding safety limits. Affected lots manufactured in Spain for US distribution.
Breckenridge Pharmaceutical recalls 60mg Duloxetine Delayed-Release Capsules due to potential N-nitroso-duloxetine impurity above FDA limits. Affected lots: NDC 82009-032-10, Lot 240539C (expiring 1/31/2027).
Breckenridge Pharmaceuticals recalls 60mg Duloxetine Delayed-Release Capsules due to N-nitroso-duloxetine impurity exceeding safety limits. Affected lots manufactured in Spain, distributed in the US. No specific remedy stated in official notice.
Breckenridge Pharmaceuticals recalls 40mg Duloxetine capsules due to potential N-nitroso impurity above FDA limits. Affected lots may pose health risks; contact for details.
Breckenridge Pharmaceutical recalls 30mg Duloxetine Delayed-Release Capsules with nitrosamine impurity above safety limits. Affected lots may cause serious health risks. Contact for return instructions.
Breckenridge Pharmaceutical recalls 60mg Duloxetine Delayed-Release Capsules due to nitrosamine impurity exceeding safety limits. Affected lots manufactured in 2024 with April 2027 expiration.
Breckenridge Pharmaceutical recalls 30mg Duloxetine capsules due to potential nitrosamine impurity. Affected lots may pose health risks; contact for return instructions.
Breckenridge recalls 60mg Duloxetine Delayed-Release Capsules with N-nitroso-duloxetine impurity above FDA limits. Stop using affected lots to avoid potential health risks.
Breckenridge recalls 30mg Duloxetine Delayed-Release Capsules with N-nitroso impurity above FDA limits. Affected lots: 240225C (exp 01/2027). Stop using immediately if you have these capsules.
Breckenridge recalls 20mg Duloxetine capsules with N-nitroso impurity above FDA limits. Stop using if you have affected lots. Details: NDC 51991-746-05, Lot 240098C.
Breckenridge Pharmaceuticals recalls 60mg Duloxetine capsules due to potential N-nitroso impurity exceeding FDA safety limits. Affected lots may pose health risks.
Breckenridge recalls 30mg Duloxetine capsules (NDC 51991-747-90) due to N-nitroso-duloxetine impurity exceeding FDA limits. Affected lots may pose health risks.
Breckenridge Pharmaceutical recalls 20mg Duloxetine capsules due to potential N-nitroso impurity exceeding FDA safety limits. Affected lots may pose health risks.
Breckenridge Pharmaceutical recalls 60mg Duloxetine capsules due to potential N-nitroso impurity above FDA limits. Affected lots: 230035C (exp 11/30/2025) and 230101C (exp 12/31/2025).
Breckenridge Pharmaceutical recalls 20mg Duloxetine capsules due to potential N-nitroso impurity exceeding FDA safety limits. Affected bottles have NDC 51991-746-05 and expire Feb 2025.
Breckenridge recalls 30mg Duloxetine Delayed-Release Capsules due to potential N-nitroso impurity above FDA limits. Affected bottles have specific NDC numbers and expiration dates.
Breckenridge Pharmaceutical recalls 20mg Clobazam tablets due to potential cross contamination. Affected lots manufactured in India, distributed in the US. Check NDC 51991-901-01 and lot #5210147.
Breckenridge Pharmaceutical recalls 10mg Clobazam tablets due to potential cross contamination. Affected lots manufactured in India, distributed in the US. Consumers should contact for details.
Breckenridge Pharmaceutical recalls 2mg Alprazolam tablets due to potential cross contamination. Affected lots from 2023-2025; check NDC numbers for details.
Breckenridge Pharmaceutical recalls 0.5mg Alprazolam tablets due to potential cross contamination. Affected lots have specific NDC numbers and expiration dates. Consumers should check their product details.
Breckenridge Pharmaceutical recalls 0.25mg Alprazolam tablets due to potential cross contamination from manufacturing. Affected lots include specific NDC numbers and expiration dates. Consumers should check their product details.
Breckenridge Pharmaceutical recalls 1mg Alprazolam tablets (NDC 51991-0706-01, 05, 10) due to potential cross contamination. Rx only, manufactured in India. Check lot numbers for affected batches.
